单 位：
天津市食品生物技术重点实验室天津商业大学生物技术与食品科学学院
关键词：
酪蛋白糖巨肽(CGMP);炎症性肠病(IBD);免疫调节;肠道菌群
摘 要：
乳源酪蛋白糖巨肽(CGMP)主要是κ-酪蛋白经凝乳酶降解产生的一类含有糖链的多肽,具有许多的生理活性功能和独特的营养特性,可广泛地应用于保健食品和医药品。本文首先概括CGMP的来源、结构特点及其研究开发现状,从炎症性肠病(IBD)的免疫病理机制的角度,对本实验室和国外在CGMP调理、改善和治疗IBD的相关研究进行系统地介绍,提出CGMP在一定程度上为IBD的生物免疫治疗提供了新的途径以及展示其广阔的开发前景。
译 名：
Research Progress in Bovine Casein Glycomacropeptide for the Improvement of Inflammatory Bowel Disease
作 者：
ZHU Chen-chen,CHEN Qing-sen(Tianjin Key Laboratory of Food Biotechnology,College of Biotechnology and Food Science, Tianjin University of Commerce,Tianjin 300134,China)
关键词：
casein glycomacropeptide(CGMP);inflammatory bowel disease(IBD);immunoregulation;intestinal flora
摘 要：
Casein glycomacropeptide(CGMP) is mainly a class of peptides bearing carbohydrate chains derived from the hydrolysis of κ-casein by tenet.Because CGMP has many physiological functions and unique nutritional properties,it can be widely used in the fields of functional food and medicine.CGMP has been reported to have anti-inflammatory activity such as improvement and immunotherapy on inflammatory bowel disease(IBD).In this paper,the sources,structural characteristics and current research status of CGMP are outlined.Recent research advances in the regulatory,improving and therapeutic effects of CGMP on IBD are reviewed.Moreover,the future development prospects of CGMP are also proposed.
